Latest News - Biogen
Top Corporates Hub
Biogen
Systemic Lupus Erythematosus Market at a Turning Point as 6 Late-Stage Emerging Therapies Set to Redefine Treatment Landscape | DelveInsight
09.07.2026 14:31
Systemic lupus erythematosus (SLE) is a chronic, complex autoimmune disease that can affect multiple organ systems, with disease severity and clinical manifestations varying considerably among patients. Despite significant advances in understanding its pathophysiology, SLE remains incurable, and current treatment strategies primarily focus on controlling disease activity, achieving remission or low disease activity, preventing irreversible organ damage, minimizing flares, and improving patients'
Biogen's Q2 2026 Earnings: What to Expect
09.07.2026 12:28
Biogen is poised to announce its second-quarter results later this month, and analysts predict a double-digit drop in the company’s bottom-line figure.
Here is Why Biogen (BIIB) is One of the Most Undervalued NASDAQ Stocks to Buy Right Now
05.07.2026 12:59
Biogen Inc. (NASDAQ:BIIB) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On June 29, it was reported that Biogen is scaling back Apellis Pharmaceuticals’ research pipeline and reducing its R&D staff, weeks after completing a $5.6 billion acquisition of the company. Biogen has suspended several legacy research programs, including Phase […]
Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.
04.07.2026 08:22
This could be a key move for future growth.
1 S&P 500 Stock with Promising Prospects and 2 We Question
02.07.2026 09:32
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.
Is Biogen (BIIB) Priced Near Fair Value After Its 57% Run?
02.07.2026 07:14
Biogen stock has delivered a strong 57.5% return over the past year, and with the current valuation checks painting a mixed picture rather than a clear bargain or clear overvaluation, investors are weighing how much of the recent Alzheimer’s and immunology news is already reflected in the price. Over the last 12 months, Biogen has returned 57.5%, which puts a spotlight on whether today’s share price still offers an attractive entry point or mainly reflects recent optimism. On the upside,...
Biogen (BIIB) To Share New Alzheimer’s Data At AAIC 2026
02.07.2026 01:18
Biogen (NasdaqGS:BIIB) plans to present new investigational data from its Alzheimer’s portfolio at AAIC 2026. The company will share detailed Phase 2 CELIA results for diranersen, a tau-targeting therapy. Biogen will also present real-world evidence on subcutaneous lecanemab, including usage patterns and long-term outcomes. For investors tracking Biogen, the AAIC 2026 agenda centers on two core Alzheimer’s assets that are central to the company’s neurodegeneration focus. Diranersen targets...
Biogen (BIIB) Moves 7.0% Higher: Will This Strength Last?
29.06.2026 12:07
Biogen (BIIB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Biogen trims Apellis pipeline and R&D team after $5.6bn takeover
29.06.2026 11:42
The pharma company plans to pause or terminate investment in most of Apellis’ legacy research programmes.
Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026, Including Phase 2 CELIA Data for Diranersen
29.06.2026 10:59
Diranersen presentation will feature Phase 2 CELIA data in early Alzheimer’s disease, including clinical, biomarker and safety results for Biogen’s investigational tau-targeting ASO, following topline results announced in May 2026Lecanemab presentations will highlight emerging data on subcutaneous administration and real-world use, including practical treatment considerations, at-home administration, three-year LEADER data, maintenance dosing and patient experienceAdvances across Biogen’s Alzhei
Biogen To Present New Data Across Alzheimer’s Disease Portfolio At AAIC 2026, Presentations To Include Data From Phase 2 CELIA Study Evaluating Diranersen, And New Analyses From Studies Of LEQEMBI
29.06.2026 07:01
Diranersen presentation will feature Phase 2 CELIA data in early Alzheimer’s disease, including clinical, biomarker and safety results for Biogen’s investigational tau-targeting ASO, following topline results announced
Needham Maintains Buy on Biogen, Raises Price Target to $256
29.06.2026 06:08
Needham analyst Ami Fadia maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $255 to $256.
Axtria Ignite 2026: 450+ Life Sciences Leaders Convene With a Contrarian Message -- Fix the Foundation Before You Scale AI
25.06.2026 12:15
Axtria Inc., a global leader in AI-first data & analytics solutions and platforms for the life sciences industry, hosted Axtria Ignite 2026 on June 10 and 11 at the Princeton Marriott at Forrestal under the theme "Industrializing Intelligence: The Agentic Enterprise." More than 450 executives from over 100 leading life sciences, MedTech, and biotech organizations gathered to work through the harder question of 2026: what must be true before an enterprise can trust AI to run at machine speed.
Biogen (BIIB) Stock Could Be 10.3% Undervalued on Its Pipeline Narrative
20.06.2026 01:10
Biogen Stock Performance Snapshot Biogen (BIIB) has drawn investor attention after a recent move in its share price, with the stock closing at US$196.58. That level sits against a backdrop of mixed short and longer term returns. See our latest analysis for Biogen. Short term momentum for Biogen looks softer, with the 1 day and 7 day share price returns both slightly negative, while the 1 month and year to date share price returns remain positive and the 1 year total shareholder return is...
Biogen to acquire RayThera for up to $1bn
19.06.2026 09:48
The proposed acquisition will add anti-inflammatory candidates to Biogen, including RayThera’s lead asset.
Biogen to Acquire RayThera in Up to $1 Billion Deal to Expand Immunology Pipeline
18.06.2026 10:39
Biogen (BIIB) agreed to acquire private biotechnology company RayThera in a deal worth up to $1 bill
BIIB Stock: Biogen Strengthens Immunology Pipeline In Up To $1B RayThera Deal
18.06.2026 00:03
The deal includes an upfront payment plus milestone payments tied primarily to clinical and regulatory successes.
Biogen Canada disappointed by outcome of pan-Canadian Pharmaceutical Alliance negotiations for SKYCLARYS™
16.06.2026 13:05
Biogen Canada Inc. is disappointed that negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for SKYCLARYS™ (omaveloxolone) have concluded without reaching an agreement.
What Makes Denali Therapeutics (DNLI) One of the Best AI Driven Biotech Names
11.06.2026 10:20
Denali Therapeutics Inc. (NASDAQ:DNLI) is one of the 10 best AI driven biotech stocks to invest in. On May 22, Denali Therapeutics Inc. (NASDAQ:DNLI) halted its joint work with Biogen Inc. (NASDAQ:BIIB), around the development of BIIB122 for idiopathic Parkinson’s disease. The decision came after topline results from the Phase 2b LUMA trial showed that […]
EVERSANA Strengthens Commitment to Driving Market Access Growth with Addition of Industry Expert Jen Norton
09.06.2026 12:16
EVERSANA®, a leading global provider of commercial services to the life sciences industry, today announced the expansion of its already leading market access offering with the appointment of Jen Norton as President, Market Access & Value. In this new role, Norton will lead the development of a dedicated, technology-first fully integrated market access business unit, uniting EVERSANA's comprehensive services to help clients navigate the complex global pricing and access landscape.